FOUNDED IN OCTOBER 2018 BY PROFESSOR BENGT SAMUELSSON, A NOBEL PRICE LAUREATE, PROFESSOR JAN-CHRISTER JANSON, DR. GU MING AND HER TEAM. ENLITISA IS A CHINESE-SWEDISH COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR INFLAMMATORY AND FIBROTIC DISEASES WITH HIGH UNMET MEDICAL NEED

Improving lives for patients with serious inflammatory and fibrotic diseases

EnliTISA

About EnliTISA

EnliTISA’s vision is to improve the lives of patients with inflammatory and fibrotic diseases through the discovery and development of breakthrough therapies.

EnliTISA is a clinical stage biopharmaceutical company focused on developing novel therapeutics with a primary focus on inflammatory and fibrotic conditions with unmet medical needs. EnliTISA, based in Shanghai, China, was founded by Chinese and Swedish team members in 2021, and is focusing on anti-inflammatory and anti-fibrosis multi-innovative drug development. The Chinese-Swedish team collaborates on pre-clinical and clinical development of drugs in China, Europe and the US. All projects in the pipeline are based on the inventions made by the EnliTISA team. By now, twelve patent applications have been filed and two patents in China and one in US have been granted.

2021

Founded in

International invention patents

R & D Innovation

Original research R & D pipeline UP818 Montelukast sodium

Our team

Anders Kärnell

Stephen McNeeney:IP attorney

Potter Clarkson Intellectual Property Office, UK

· Has cooperated with the company for 5 and a half years, responsible for the company's intellectual property strategy construction and international PCT application, completed 12 international invention patent applications, 2 Chinese patent authorizations, and 1 US patent authorization. IP due diligence and negotiation to support Chinese and overseas transactions · Supported over 70 clients in IP due diligence and negotiation of intercontinental licensing transactions

The world's leading original innovative
drug enterprise for inflammation and injury

Welcome to join us

News

The world's leading original innovative drug enterprise for inflammation and injury

Completion of first patient first visit in phase II clinical trial of TISA-818-Inj for the treatment of acute respiratory distress syndrome

The Phase II clinical trial of TISA-818-Inj for the treatment of acute respiratory distress syndrome (ARDS) recently completed first patient first visit (FPFV), which was led by Professor Zhan Qingyuan of the China-Japan Friendship Hospital and sponsored by EnliTISA (Shang Hai) Pharmaceutical Co., Ltd (Abbreviated as EnliTISA).

Never forget the original intention and forge ahead with perseverance—— Housewarming of Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (EnliTISA)

The inauguration ceremony of EnliTISA’s relocation was held on November 10, 2022. Chairman Dr. Gu Ming delivered a grand speech and witnessed this memorable moment together with all staff.

Tel:+86-021-33758853

Add:Room 201, 202, 203, BuildingA, Block1, No. 800, Qingdai Road, Pudong New District, Shanghai

Company
- Company
- Team
- Culture
- Honor
R & D
Our focus
- IPF
- ALI
- RP
- AS
- DFUs
News
- Enterprise dynamics
- Press report
Development
- Recruit
- Staff style
Contact